TQB 3823
Alternative Names: TQB-3823Latest Information Update: 28 Sep 2024
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Prostate cancer
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (PO, Tablet)
- 19 Jul 2023 Chia Tai Tianqing Pharmaceutical Group terminates a Phase-I/II clinical trials in Prostate cancer (Combination therapy, Metastatic disease, Hormone refractory) in China (PO) (NCT05405439)
- 25 Aug 2022 Phase-I/II clinical trials in Prostate cancer (Combination therapy, Metastatic disease, Hormone refractory) in China (PO) (NCT05405439)